I78.0 Hereditary hemorrhagic telangiectasia

Name of the Condition

• Hereditary hemorrhagic telangiectasia

Summary

Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by abnormal blood vessel formations, leading to fragile, dilated vessels that can rupture and cause bleeding. These vascular malformations typically affect the skin, mucous membranes, and internal organs, including the lungs, liver, and brain.

Causes

HHT is caused by mutations in genes responsible for blood vessel development, such as ENG, ACVRL1, or SMAD4. These genetic changes disrupt the normal formation and repair of blood vessels, resulting in the characteristic telangiectasias and arteriovenous malformations (AVMs).

Risk Factors

• Family history of HHT: Inherited in an autosomal dominant pattern.
• Genetic mutations: Specific mutations in ENG, ACVRL1, or SMAD4 genes increase risk.
• Age: Symptoms often appear in childhood or early adulthood but may develop later.

Symptoms

• Recurrent nosebleeds (epistaxis): Often the earliest and most common symptom.
• Telangiectasias: Small, visible red spots on the skin or mucous membranes (e.g., lips, tongue, fingers).
• Gastrointestinal bleeding: May cause anemia or black, tarry stools.
• Organ-specific symptoms: Coughing up blood (pulmonary AVMs), abdominal pain (liver AVMs), or neurological symptoms (brain AVMs).

Diagnosis

Diagnosis involves a combination of clinical evaluation, family history, and imaging studies. Criteria include recurrent nosebleeds, telangiectasias, visceral AVMs, and a first-degree relative with HHT. Imaging (e.g., CT, MRI, or angiography) confirms AVMs in organs like the lungs, liver, or brain.

Treatment Options

• Epistaxis management: Topical treatments, nasal moisturizers, or laser therapy.
• Iron supplementation: To address anemia from chronic bleeding.
• Endovascular procedures: Embolization to treat pulmonary or gastrointestinal AVMs.
• Surgical intervention: For severe or symptomatic AVMs in the brain or other organs.
• Genetic counseling: Recommended for affected individuals and their families.

Prognosis and Follow-Up

Prognosis varies depending on the severity and location of AVMs. Regular monitoring (e.g., imaging, blood tests) is essential to detect and manage complications. Early intervention can reduce morbidity, but lifelong surveillance is typically required.

Complications

• Severe or life-threatening bleeding: From pulmonary, gastrointestinal, or cerebral AVMs.
• High-output heart failure: Due to large liver AVMs.
• Stroke or brain abscess: From cerebral AVMs.
• Pulmonary hypertension: Secondary to pulmonary AVMs.

Lifestyle & Prevention

• Avoid blood-thinning medications (e.g., aspirin) unless prescribed, as they may increase bleeding risk.
• Use humidifiers to reduce nasal dryness and epistaxis frequency.
• Protect the skin from trauma to minimize telangiectasia-related bleeding.
• Maintain regular follow-up with a healthcare provider for monitoring.

When to Seek Professional Help

Seek immediate medical attention for:

• Sudden, severe bleeding (e.g., coughing up blood, heavy nosebleeds).
• Neurological symptoms (e.g., headache, weakness, or confusion).
• Signs of anemia (e.g., fatigue, dizziness, or pale skin).
• Unexplained abdominal pain or swelling.

Tips for Medical Coders

When coding for hereditary hemorrhagic telangiectasia (ICD-10-CM code I78.0), ensure documentation supports the diagnosis, including clinical findings (e.g., telangiectasias, epistaxis) and genetic testing results if available. Note the presence of organ-specific AVMs (e.g., pulmonary, hepatic) as they may require additional coding. Verify that the diagnosis aligns with established clinical criteria to support accurate code assignment.